Results 141 to 150 of about 168,901 (301)

Efficient and Specific PDGFRβ‐Targeting Dual‐Mode T1‐T2 MRI Nanoprobe for Early Diagnosis of Non‐Alcoholic Fatty Liver

Advanced Science, EarlyView.
The Fe3O4/Gd@BSA‐pPB nanoprobe leverages biomimetic mineralization and targets hepatic stellate cells (HSCs) through PDGFRβ, offering superior enrichment in fibrotic regions. This targeted delivery overcomes biological barriers, enhancing both the accuracy and sensitivity of MRI imaging at early disease stages.
Zehua Li, Tongwei Zhang, Tongxiang Tao, Yaxuan Liu, Haining Xia, Sajid ur Rehman, Zeyong Guo, Jing Zhang, Ruiguo Chen, Zhan Zhang, Junfeng Wang, Kun Ma   +11 more
wiley   +1 more source

Concordance of breast cancer biomarker testing in core needle biopsy and surgical specimens: A single institution experience

Cancer Medicine, Volume 11, Issue 24, Page 4954-4965, December 2022., 2022
Retesting estrogen receptor and HER2 status provides more clinical benefit than retesting progesterone receptor status. We propose guidelines for retesting receptor profiles to aid patient care management decisions, prioritize clinical benefits, and minimize healthcare costs.
Jessica A. Slostad, Nicole K. Yun, Aimee E. Schad, Surbhi Warrior, Louis F. Fogg, Ruta Rao   +5 more
wiley   +1 more source

COPS5 Triggers Ferroptosis Defense by Stabilizing MK2 in Hepatocellular Carcinoma

Advanced Science, EarlyView.
COPS5, which is overexpressed in HCC in an amplification‐ and ATF4‐dependent manner, stabilizes MK2 through deubiquitination and, in turn, induces HSPB1 activation, protecting HCC cells from ferroptosis and thus promoting sorafenib resistance and tumor progression. Abstract Sorafenib, which is proven to serve as a potent ferroptosis inducer, is used as
Ai‐Ling Luo, Wen‐Ying Zheng, Qiong Zhang, Yan Yuan, Mei‐Qi Li, Kai Du, An‐Ran Gao, Li‐Jun Pei, Jie Xie, Wen‐Hao Chen, Long Zhang, Xiu‐Zhu Guo, Xiao‐Ran Yang, Chao Zeng, Guo‐Hua Yang, Min Deng   +15 more
wiley   +1 more source

Low-Grade and High-Grade Invasive Ductal Carcinomas of the Breast Follow Divergent routes of Progression

Cancer Biology & Medicine, 2011
Low-grade invasive ductal carcinoma is almost diploid, and has frequent losses of chromosome 16q, which is shared by other precancerous lesions of the mammary gland such as flat epithelial atypia (FEA), atypical ductal hyperplasia (ADH), and low-nuclear ...
Yun NIU, Estifanos P.GEBREAMLAK
doaj   +1 more source

Ductal carcinoma in situ revisited

The Breast, 2000
Since our review appeared in The Breast, further information from randomized studies has become available. The EORTC data have been published and are summarized in Table 1. This was a randomized trial assessing the value of radiotherapy after breast conserving surgery.
D.L. Page, J.M. Dixon
openaire   +3 more sources

Extracellular Vesicular Delta‐Like Ligand 3 and Subtype Transcription Factors for Small Cell Lung Cancer Diagnosis

Advanced Science, EarlyView.
Small cell lung cancer (SCLC) harbors high molecular heterogeneity. Using a new liquid biopsy assay, SCLC subtypes can be identified by measuring mRNA of subtype transcription factors (ASCL1, POU2F3, and NEUROD1) in exosome‐rich extracellular vesicles. Combining with Delta‐like ligand 3 (DLL3) mRNA in exosomes and its membrane protein in extracellular ...
Hong Li, Chi‐Ling Chiang, Kwang Joo Kwak, Hsin‐Lun Lee, Xinyu Wang, Giulia Romano, Michela Saviana, Robin Toft, Tai‐Shan Cheng, Yuehshih Chang, Bi‐Da Hsiang, Guan‐Wan Liu, Xiaokui Mo, Yifan Ma, Junjie Pan, Xilal Y. Rima, Truc Nguyen Kim, Eduardo Reategui, Chia‐Ning Shen, Yeh‐Shiu Chu, Carlo Croce, Peter Mu‐Hsin Chang, Yi‐Chen Yeh, David P. Carbone, Chi‐Ying F. Huang, Chi‐Lu Chiang, Patrick Nana‐Sinkam, L. James Lee   +27 more
wiley   +1 more source

CCN1 Enhances Tumor Immunosuppression through Collagen‐Mediated Chemokine Secretion in Pancreatic Cancer

Advanced Science, EarlyView.
CCN1 modulates the tumor microenvironment in pancreatic cancer by promoting collagen‐dependent chemokine production, thereby facilitating immune evasion. Deletion of CCN1 not only suppresses tumor growth but also enhances immune cell infiltration and increases tumor sensitivity to both chemotherapy and immunotherapy.
Hongjie Fan, Huzi Zhao, Lili Gao, Yucheng Dong, Pei Zhang, Pengfei Yu, Yunfei Ji, Zhe‐Sheng Chen, Xinmiao Liang, Yang Chen   +9 more
wiley   +1 more source

Effectiveness of triennial screening with clinical breast examination: 14‐years follow‐up outcomes of randomized clinical trial in Trivandrum, India

Cancer, Volume 129, Issue 2, Page 272-282, 15 January 2023., 2023
Abstract Background This study presents the preliminary results of a randomized controlled trial (RCT) initiated in January 2006 in India to evaluate the effectiveness of clinical breast examination (CBE) in reducing breast cancer mortality as compared to a no‐screening control group reported significant downstaging in the intervention group.
Kunnambath Ramadas, Partha Basu, Beela S. Mathew, Richard Muwonge, Muraleedharan Venugopal, Aparna M. Prakasan, Rafi Malu, Eric Lucas, Paul Augustine, Rari P. Mony, Somanathan Thara, Rengaswamy Sankaranarayanan   +11 more
wiley   +1 more source

Changes in mRNA expression of oncogenesis driver genes in atypical ductal breast hyperplasia

Опухоли женской репродуктивной системы
Background. Atypical ductal hyperplasia is a relatively common breast lesion that increases the risk of breast cancer by 3.5 to 5 times. Genomic rearrangements underlying the development of atypical proliferative lesions and breast cancer lead to gene ...
O. V. Burmenskaya, V. V. Kometova, A. A. Smetnik, V. V. Rodionov, D. Yu. Trofimov, L. A. Ashrafyan, G. T. Sukhikh   +6 more
doaj   +1 more source

Plasma DNMT1 Activity for Assessing Tumor Burden and Predicting Neoadjuvant Therapy Response in Breast Cancer

Advanced Science, EarlyView.
In this work, a detection method is presented for the activity of plasma DNA methyltransferase 1 (DNMT1), namely DNMT1 Identification by Variable Activity (DIVA). DIVA can detect plasma DNMT1 at levels as low as 10−7 U mL−1, also it successfully evaluated tumor burden and predicted the neoadjuvant therapy responses of breast cancer patients.
Yingran Wang, Guozhi Zhang, Zhizhao Zhang, Mengsi Zhang, Jiao Chen, Ke Wang, Lu Liu, Jing Bao, Ming Chen, Xiaowei Qi, Mingxuan Gao   +10 more
wiley   +1 more source